– USA, TX – Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the appointment of Rod Cotton to its Board of Directors, effective immediately, bringing the board to nine members.
“Rod’s broad range of leadership experience in the diagnostic industry will be a significant benefit to our board. We are pleased to welcome him,” said CEO, Derek Maetzold.
The Company also announced that Mara Aspinall will not stand for re-election to its Board.
About Rodney Cotton
Rod Cotton is a leader in the diagnostics industry who is known for his holistic perspective, bias for action in the face of challenges, and commitment to agile processes. He built a successful career at Roche spanning more than two decades and culminating in the role of SVP of head of strategy & transformation, and chief of staff to the CEO for Roche Diagnostics, the North American headquarters of the world’s largest diagnostics company. While at Roche, Cotton led key enterprise initiatives, such as milestone corporate communications, health equity coalitions, the U.S./Roche Group audit, and global/U.S. acquisition integrations. With 40-plus years of experience, he drove the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 total reports, managed a P&L of more than $1 billion in revenue, and served as a key member of the senior leadership team executing the most significant restructuring of the company in two decades. In the face of the COVID-19 pandemic, Cotton and his team at Roche accelerated six ground-breaking products in 11 months, including the first launch of the market’s most accurate and in-demand molecular diagnostic test. He also solved challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self-manufacturing in line with testing guidelines. He received The Sagamore of the Wabash Award, one of the highest Indiana State honors, bestowed by Indiana Governor Eric J. Holcomb.
Rod Cotton currently serves on the board of directors of Eisai Pharmaceutical U.S., a research and development pharmaceutical company and subsidiary of Eisai Company, Ltd., Orchard Software, a private equity-backed health technology company owned by Francisco Partners; an advisory board member to Flo2 Ventures, a venture capital-backed healthcare and health equity accelerator; and serves as a member of the board of directors and on three board committees (Audit, Compliance & Finance; Governance & Equity; and Quality of Care) for Community Health Network.
Rod Cotton holds an MBA from California State University, Dominguez Hills, an M.S. in strategic management from the University of Southern California, and a B.A. in biological sciences & technology from the University of California at Santa Barbara.
About Castle Biosciences
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees, and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis, and related conditions.
SOURCE: https://www.castlebiosciences.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.